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Abstract
Background: Unsupervised learning can discover various unseen diseases, relying
on large-scale unannotated medical images of healthy subjects. Towards this,
unsupervised methods reconstruct a 2D/3D single medical image to detect
outliers either in the learned feature space or from high reconstruction loss.
However, without considering continuity between multiple adjacent slices, they
cannot directly discriminate diseases composed of the accumulation of subtle
anatomical anomalies, such as Alzheimer’s Disease (AD). Moreover, no study has
shown how unsupervised anomaly detection is associated with either disease
stages, various (i.e., more than two types of) diseases, or multi-sequence
Magnetic Resonance Imaging (MRI) scans.
Results: We propose unsupervised Medical Anomaly Detection Generative
Adversarial Network (MADGAN), a novel two-step method using GAN-based
multiple adjacent brain MRI slice reconstruction to detect various diseases at
different stages on multi-sequence structural MRI: (Reconstruction) Wasserstein
loss with Gradient Penalty + 100 `1 loss—trained on 3 healthy brain axial MRI
slices to reconstruct the next 3 ones—reconstructs unseen healthy/abnormal
scans; (Diagnosis) Average `2 loss per scan discriminates them, comparing the
ground truth/reconstructed slices. For training, we use 1, 133 healthy
T1-weighted (T1) and 135 healthy contrast-enhanced T1 (T1c) brain MRI scans.
Our Self-Attention MADGAN can detect AD on T1 scans at a very early stage,
Mild Cognitive Impairment (MCI), with Area Under the Curve (AUC) 0.727, and
AD at a late stage with AUC 0.894, while detecting brain metastases on T1c
scans with AUC 0.921.
Conclusions: Similar to physicians’ way of performing a diagnosis, using massive
healthy training data, our first multiple MRI slice reconstruction approach,
MADGAN, can reliably predict the next 3 slices from the previous 3 ones only for
unseen healthy images. As the first unsupervised various disease diagnosis,
MADGAN can reliably detect the accumulation of subtle anatomical anomalies
and hyper-intense enhancing lesions, such as (especially late-stage) AD and brain
metastases on multi-sequence MRI scans.
Keywords: Generative adversarial networks; Self-attention; Unsupervised
anomaly detection; Brain MRI reconstruction; Various disease diagnosis
Background
Machine Learning has revolutionized life science research, especially in Neuroimag-
ing and Bioinformatics [1, 2], such as by modeling interactions between whole
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brain genomics/imaging [3, 4] and identifying Alzheimer’s Disease (AD)-related
proteins [5]. Especially, Deep Learning can achieve accurate computer-assisted di-
agnosis when large-scale annotated training samples are available. In Medical Imag-
ing, unfortunately, preparing such massive annotated datasets is often unfeasible
[6, 7]; to tackle this pervasive problem, researchers have proposed various data
augmentation techniques, including Generative Adversarial Network (GAN)-based
ones [8, 9, 10, 11, 12] ; alternatively, Rauschecker et al. combined Convolutional
Neural Networks (CNNs), feature engineering, and expert-knowledge Bayesian net-
work to derive brain Magnetic Resonance Imaging (MRI) differential diagnoses
that approach neuroradiologists’ accuracy for 19 diseases. However, even exploiting
these techniques, supervised learning still requires many images with pathological
features, even for rare disease, to make a reliable diagnosis; nevertheless, it can
only detect already-learned specific pathologies. In this regard, as physicians notice
previously unseen anomaly examples using prior information on healthy body struc-
ture, unsupervised anomaly detection methods leveraging only large-scale healthy
images can discover and alert overlooked diseases when their generalization fails.
Towards this, researchers reconstructed a single medical image via GANs [13],
AutoEncoders (AEs) [14], or combining them, since GANs can generate realistic
images and AEs, especially Variational AEs (VAEs), can directly map data onto its
latent representation [15]; then, unseen images were scored by comparing them with
reconstructed ones to discriminate a pathological image distribution (i.e., outliers
either in the learned feature space or from high reconstruction loss). However, those
single image reconstruction methods mainly target diseases easy-to-detect from a
single image even for non-expert human observers, such as glioblastoma on MR
images [15] and lung cancer on Computed Tomography (CT) images [14]. Without
considering continuity between multiple adjacent images, they cannot directly dis-
criminate diseases composed of the accumulation of subtle anatomical anomalies,
such as AD. Moreover, no study has shown so far how unsupervised anomaly de-
tection is associated with either disease stages, various (i.e., more than 2 types of)
diseases, or multi-sequence MRI scans.
Therefore, this paper proposes unsupervised Medical Anomaly Detection GAN
(MADGAN), a novel two-step method using GAN-based multiple adjacent brain
MRI slice reconstruction to detect various diseases at various stages on multi-
sequence structural MRI (Fig. 1): (Reconstruction) Wasserstein loss with Gradi-
ent Penalty (WGAN-GP) [16, 17] + 100 `1 loss—trained on 3 healthy brain axial
MRI slices to reconstruct the next 3 ones—reconstructs unseen healthy/abnormal
scans; the `1 loss generalizes well only for unseen images with a similar distribution
to the training images while the WGAN-GP loss captures recognizable structure;
(Diagnosis) Average `2 loss per scan discriminates them, comparing the ground
truth/reconstructed slices; the `2 loss clearly discriminates the healthy/abnormal
scans as squared error becomes huge for outliers. Using Receiver Operating Charac-
teristics (ROCs) and their Area Under the Curves (AUCs), we evaluate the diagnosis
performance of AD on T1-weighted (T1) MRI scans, and brain metastases/various
diseases (e.g., small infarctions, aneurysms) on contrast-enhanced T1 (T1c) MRI
scans. Using 1, 133 healthy T1 and 135 healthy T1c scans for training, our Self-
Attention (SA) MADGAN approach can detect AD at a very early stage, Mild
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Cognitive Impairment (MCI), with AUC 0.727, and AD at a late stage with AUC
0.894, while detecting brain metastases with AUC 0.921.
Contributions. Our main contributions are as follows:
• MRI Slice Reconstruction: This first multiple MRI slice reconstruction
approach can reliably predict the next 3 slices from the previous 3 ones only
for unseen images similar to training data by combining SAGAN and `1 loss.
• Unsupervised Anomaly Detection: This first unsupervised multi-stage
anomaly detection reveals that, like physicians’ way of performing a diagno-
sis, massive healthy data can aid early diagnosis, such as of MCI, while also
detecting late-stage disease much more accurately by discriminating with `2
loss.
• Various Disease Diagnosis: This first unsupervised various disease diagno-
sis can reliably detect the accumulation of subtle anatomical anomalies and
hyper-intense enhancing lesions, such as AD and brain metastases on multi-
sequence MRI scans.
Related work
Alzheimer’s disease diagnosis
Even though the clinical, social, and economic impact of early AD diagnosis is of
paramount importance [18]—primarily associated with MCI detection [19]—it gen-
erally relies on subjective assessment by physicians (e.g., neurologists, geriatricians,
and psychiatrists). Towards quantitative and reproducible approaches, many tra-
ditional supervised Machine Learning-based methods—which relies on handcrafted
MRI-derived features—were proposed in the literature [20, 21]. In this context,
diffusion-weighted MRI tractography enables reconstructing the brain’s physical
connections that can be subsequently investigated by complex network-based tech-
niques. Lella et al. [22] employed the whole brain structural communicability as
a graph-based metric to describe the AD-relevant brain connectivity disruption.
This approach achieved comparable performance with classic Machine Learning
models—namely, Support Vector Machines, Random Forests, and Artificial Neural
Networks—in terms of classification and feature importance analysis.
In the latest years, Deep Learning has achieved outstanding performance by ex-
ploiting more multiple levels of abstraction and descriptive embeddings in a hierar-
chy of increasingly complex features [23]: Liu et al. devised a semi-supervised CNN
to significantly reduce the need for labeled training data [24]; for clinical decision-
making tasks, Suk et al. integrated multiple sparse regression models (i.e., Deep
Ensemble Sparse Regression Network) [25]; Spasov et al. proposed a parameter-
efficient CNN for 3D separable convolutions, combining dual learning and a specific
layer to predict the conversion from MCI to AD within 3 years [26]; different from
CNN-based approaches, Parisot used a semi-supervised Graph Convolutional Net-
work trained on a sub-set of labeled nodes with diagnostic outcomes to represent
sparse clinical data [27]. However, to the best of our knowledge, no existing work has
conducted fully unsupervised anomaly detection for AD diagnosis since capturing
subtle anatomical differences between MCI and AD is challenging.
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Unsupervised medical anomaly detection
Unsupervised disease diagnosis is challenging because it requires estimating healthy
anatomy’s normative distributions only from healthy examples to detect outliers
either in the learned feature space or from high reconstruction loss. The latest
advances in Deep Learning, mostly GANs [8] and VAEs [28], have allowed for
the accurate estimation of the high-dimensional healthy distributions. Except for
discriminative-boundary-based approaches including [29], almost all unsupervised
medical anomaly detection studies have leveraged reconstruction: as pioneering re-
search, Schlegl et al. proposed AnoGAN to detect outliers in the learned feature
space of the GAN [30]; then, the same authors presented fast AnoGAN that can effi-
ciently map query images onto the latent space [13]; since the reconstruction-based
models often suffer from many false positives, Chen et al. penalized large devia-
tions between original/reconstructed images in gliomas and stroke lesion detection
on brain MRI [31]. However, to the best of our knowledge, all previous studies
are based on 2D/3D single image reconstruction, without considering continuity
between multiple adjacent slices. Moreover, no existing work has investigated how
unsupervised anomaly detection is associated with either disease stages, various
(i.e., more than two types of) diseases, or multi-sequence MRI scans.
Self-Attention GANs (SAGANs)
Zhang et al. proposed SAGAN that deploys an SA mechanism in the genera-
tor/discriminator of a GAN to learn global and long-range dependencies for di-
verse image generation [32]; for further performance improvement, they suggested
to apply the SA modules to large feature maps. The SAGANs have shown great
promise in various tasks, such as human pose estimation [33], image colorization [34],
photo-realistic image de-quantization [35], and large-scale image generation [36].
This SAGAN trend also applies to Medical Imaging to extract multi-level features
for better super-resolution/denoising and lesion characterization: to mitigate the
problem of thin slice thickness, Kudo et al. and Li et al. applied the SA modules
to GANs on CT and MRI scans, respectively [37, 38]; similarly, in [39], the authors
proposed to fuse plane SA modules and depth SA modules for low-dose 3D CT de-
noising; Lan et al. synthesized multi-modal 3D brain images using SA conditional
GAN [39]; Ali et al. incorporated SA modules into progressive growing of GANs to
generate realistic and diverse skin lesion images for data augmentation [40]. How-
ever, to the best of our knowledge, no existing work has directly exploited the
SAGAN for medical disease diagnosis.
Datasets
AD MRI dataset: OASIS-3
We use a longitudinal dataset of 176×240/176×256 T1 brain axial MRI slices con-
taining both normal aging subjects/AD patients, extracted from the Open Access
Series of Imaging Studies-3 (OASIS-3) [41]. The 176× 240 slices are zero-padded to
reach 176× 256 pixels. Relying on Clinical Dementia Rating (CDR) [42], common
clinical scale for the staging of dementia, the subjects are comprised of:
• Unchanged CDR = 0: Cognitively healthy population;
• CDR = 0.5: Very mild dementia (∼ MCI);
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• CDR = 1: Mild dementia;
• CDR = 2: Moderate dementia.
Since our dataset is longitudinal and the same subject’s CDRs may vary (e.g.,
CDR = 0 to CDR = 0.5), we only use scans with unchanged CDR = 0 to assure
certainly healthy scans. As CDRs are not always assessed simultaneously with the
MRI acquisition, we label MRI scans with CDRs at the closest date. We only
select brain MRI slices including hippocampus/amygdala/ventricles among whole
256 axial slices per scan to avoid over-fitting from AD-irrelevant information; the
atrophy of the hippocampus/amygdala/cerebral cortex, and enlarged ventricles are
strongly associated with AD, and thus they mainly affect the AD classification
performance of Machine Learning [43]. Moreover, we discard low-quality MRI slices.
The remaining dataset is divided as follows:
• Training set: Unchanged CDR = 0 (408 subjects/1, 133 scans/57, 834 slices);
• Test set: Unchanged CDR = 0 (168 subjects/473 scans/24, 278 slices),
CDR = 0.5 (152 subjects/253 scans/13, 813 slices),
CDR = 1 (90 subjects/135 scans/7, 532 slices),
CDR = 2 (6 subjects/10 scans/500 slices).
The same subject’s scans are included in the same dataset. The datasets are strongly
biased towards healthy scans similarly to MRI inspection in the clinical routine.
During training for reconstruction, we only use the training set—structural MRI
alone—containing healthy slices to conduct unsupervised learning. We do not use
a validation set as our unsupervised diagnosis step is non-trainable.
Brain metastasis and various disease MRI dataset
This paper also uses a non-longitudinal, heterogeneous dataset of 190× 224/216×
256/256× 256/460× 460 T1c brain axial MRI slices, collected by the authors (Na-
tional Center for Global Health and Medicine, Tokyo, Japan) and currently not
publicly available for ethical restrictions. The dataset contains both healthy sub-
jects, brain metastasis patients [44], and patients with various diseases different from
brain metastases. The slices are resized to 176 × 256 pixels. The various diseases
include but are not limited to:
• Small infarctions;
• Aneurysms;
• Benign tumors;
• Hemorrhages;
• Cysts;
• White matter lesions;
• Post-operative inflammations.
Conforming to T1 slices, we also only select T1c slices including hippocampus,
amygdala, and ventricles—a large portion of various diseases also appear in the
mid-brain. The remaining dataset is divided as follows:
• Training set: Normal (135 subjects/135 scans/7, 793 slices);
• Test set: Normal (58 subjects/58 scans/3, 353 slices),
Brain Metastases (79 subjects/79 scans/4, 872 slices),
Various Diseases (66 subjects/66 scans/4, 195 slices).
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Since we cannot collect large-scale T1c scans from healthy patients like OASIS-
3 dataset, during training for reconstruction, we use both T1/T1c training sets
containing healthy slices simultaneously for the knowledge transfer. In the clinical
practice, T1c MRI is well-established in detecting various diseases, including brain
metastases [45], thanks to its high-contrast in the enhancing region—however, the
contrast agent is not suitable for screening studies. Accordingly, such inter-sequence
knowledge transfer is valuable in computer-assisted MRI diagnosis. During testing,
we make an unsupervised diagnosis on T1 and T1c scans separately.
Methods
MADGAN-based multiple adjacent brain MRI slice reconstruction
To model strong consistency in healthy brain anatomy (Fig. 1), in each scan, we
reconstruct the next 3 MRI slices from the previous 3 ones using an image-to-
image GAN (e.g., if a scan includes 40 slices si for i = 1, . . . , 40, we reconstruct
all possible 35 setups: (si)i∈{1,2,3} 7→ (si)i∈{4,5,6}; (si)i∈{2,3,4} 7→ (si)i∈{5,6,7}; . . . ;
(si)i∈{35,36,37} 7→ (si)i∈{38,39,40}). As Fig. 2 shows, our MADGAN uses a U-Net-
like [46, 47] generator with 4 convolutional layers in encoders and 4 deconvolutional
layers in decoders respectively with skip connections, as well as a discriminator with
3 decoders. We apply batch normalization to both convolution with Leaky Recti-
fied Linear Unit (ReLU) and deconvolution with ReLU. Between the designated
convolutional/deconvolutional layers and batch normalization layers, we apply SA
modules [32] for effective knowledge transfer via feature recalibration between T1
and T1c slices; we compare the MADGAN models with a different number of the SA
modules: (i) no SA modules (i.e., MADGAN); (ii) 3 (red-contoured) SA modules
(i.e., 3-SA MADGAN); (iii) 7 (red- and blue-contoured) SA modules (i.e., 7-SA
MADGAN). To confirm how reconstructed slices’ realism and anatomical continu-
ity affect medical anomaly detection, we also compare the MADGAN models with
different loss functions: (i) WGAN-GP loss + 100 `1 loss (i.e., MADGAN); (ii)
WGAN-GP loss (i.e., MADGAN w/o `1 loss).
Implementation details Each MADGAN training lasts for 1.8 × 106 steps with a
batch size of 16. We use 2.0× 10−4 learning rate for Adam optimizer [48]. Such as
in RGB images, we concatenate adjacent 3 grayscale slices into 3 channels. During
training, the generator uses two dropout [49] layers with 0.5 rate. We flip the dis-
criminator’s real/synthetic labels once in three times for robustness. The framework
is implemented on TensorFlow.
Unsupervised medical anomaly detection
During diagnosis, we use average `2 loss per scan since squared error is sensitive to
outliers and it significantly outperformed other losses (i.e., `1 loss, Dice loss, Struc-
tural Similarity loss) in our preliminary paper [50]. To evaluate its unsupervised AD
diagnosis performance on a T1 MRI test set, we show ROCs —along with the AUC
values—between CDR = 0 vs (i) all the other CDRs; (ii) CDR = 0.5; (iii) CDR
= 1; (iv) CDR = 2. We also show the AUCs under different training steps (i.e.,
150k, 300k, 600k, 900k, 1.8M steps) and confirm the effect of calculating average
`2 loss (among whole slices or continuous 10 slices exhibiting the highest loss) per
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scan. Moreover, we visualize pixelwise `2 loss between real/reconstructed 3 slices,
along with distributions of average `2 loss per scan of CDR = 0/0.5/1/2 to know
how disease stages affect its discrimination. In exactly the same manner, we evalu-
ate the diagnosis performance of brain metastases/various diseases on a T1c MRI
test set, showing ROCs/AUCs between normal vs (i) brain metastases + various
diseases; (ii) brain metastases; (iii) various diseases.
Results
Reconstructed brain MRI slices
Fig. 3 illustrates example real T1 MRI slices from a test set and their reconstruc-
tion by MADGAN and 7-SA MADGAN. Similarly, Figs. 4 and 5 show example real
T1c MRI slices and their reconstructions. Figs. 6 and 7 indicate distributions of
average `2 loss per scan on T1 and T1c scans, respectively. Thanks to `1 loss’ good
realism sacrificing diversity (i.e., generalizing well only for unseen images with a
similar distribution to training images) and WGAN-GP loss’ ability to capture rec-
ognizable structure, the MADGAN can successfully capture T1-specific appearance
and anatomical changes from the previous 3 slices. Meanwhile, the 7-SA MADGAN
tends to be less stable in keeping texture but more sensitive to abnormal anatom-
ical changes due to the SA modules’ feature recalibration, resulting in moderately
higher average `2 loss than the MADGAN.
Since the models are trained only on healthy slices, as visualized by an overim-
posed Jet colormap, reconstructing slices with higher CDRs tends to comparatively
fail, especially around hippocampus, amygdala, cerebral cortex, and ventricles due
to their insufficient atrophy after reconstruction. The T1c scans show much lower
average `2 loss than the T1 scans due to darker texture. Since most training im-
ages are the T1 slices with brighter texture than the T1c slices, reconstruction
quality clearly decreases on the T1c slices, occasionally exhibiting bright texture.
Accordingly, reconstruction failure from anomaly contributes comparatively less to
the average `2 loss, especially when local small lesions, such as brain abscess and
enhanced lesions, appear—unlike global big lesions, such as multiple cerebral in-
farction and blood component retention. However, the average `2 loss remarkably
increases on brain metastases scans due to their hyper-intensity, especially for the
7-SA MADGAN.
Unsupervised anomaly detection results
Figs. 8 and 9 show AUCs of unsupervised anomaly detection on T1 and T1c scans
under different training steps, respectively. The AUCs generally increase as training
progresses, but more SA modules require more training steps until convergence due
to their feature recalibration—7-SA MADGAN might perform even better if we
continue its training. All the best results in specific tasks, except for CDR = 0 vs
CDR = 0.5, are from the SA models (e.g., 7-SA MADGAN w/o `1 loss under 900k
steps: AUC 0.783 in CDR = 0 vs CDR = 0.5 + 1 + 2, 3-SA MADGAN under 300k
steps: AUC 0.966 in normal vs brain metastases, 3-SA MADGAN under 600k steps:
AUC 0.638 in normal vs various diseases); thus, whereas the SA models, which do
not know the task to optimize in an unsupervised manner, perform unstably, we
might use them similarly to supervised learning if we could obtain good parameters
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for a certain disease. Without `1 loss, the AUCs tend to decrease, also accompanying
large fluctuations; 7-SA MADGAN w/o `1 loss performs well on the T1 scans but
poorly on the T1c scans due to the instability.
Figs. 10 and 11 illustrate ROC curves and their AUCs on T1 and T1c scans un-
der 1.8M training steps, respectively. Since brains with higher CDRs accompany
stronger anatomical atrophy from healthy brains, their AUCs between unchanged
CDR = 0 remarkably increase as CDRs increase. MADGAN and 7-SA MADGAN
both achieves good AUCs, especially for higher CDRs—The MADGAN obtains
AUC 0.750/0.707/0.829 in CDR = 0 vs CDR = 0.5/1/2, respectively; the discrim-
ination between healthy subjects vs MCI patients (i.e., CDR = 0 vs CDR = 0.5)
is extremely difficult even in a supervised manner [43]. Whereas detecting various
diseases is difficult in an unsupervised manner, the 7-SA MADGAN outperforms
the MADGAN and achieves AUC 0.921 in brain metastases detection. As Tables 1
and 2 show, the effect of how to calculate average `2 loss (among whole slices or
continuous 10 slices exhibiting the highest loss) per scan is limited.
Discussion and conclusions
Using massive healthy data, our MADGAN-based multiple MRI slice reconstruction
can reliably discriminate AD patients from healthy subjects for the first time in an
unsupervised manner; to detect the accumulation of subtle anatomical anomalies,
our solution leverages a two-step approach: (Reconstruction) `1 loss generalizes well
only for unseen images with a similar distribution to training images while WGAN-
GP loss captures recognizable structure; (Diagnosis) `2 loss clearly discriminates
healthy/abnormal data as squared error becomes huge for outliers. Using 1, 133
healthy T1 MRI scans for training, our approach can detect AD at a very early
stage, MCI, with AUC 0.727 while detecting AD at a late stage with AUC 0.894.
Accordingly, this first unsupervised anomaly detection across different disease stages
reveals that, like physicians’ way of performing a diagnosis, large-scale healthy data
can reliably aid early diagnosis, such as of MCI, while also detecting late-stage
disease much more accurately.
To confirm its ability to also detect other various diseases, even on different MRI
sequence scans, we firstly investigate how unsupervised medical anomaly detection
is associated with various diseases and multi-sequence MRI scans, respectively. Due
to the different texture of T1/T1c slices, reconstruction quality clearly decreases on
the data-sparse T1c slices, and thus reconstruction failure from anomaly contributes
comparatively less to the average `2 loss. Nevertheless, we generally succeed to
unravel diseases hard-to-detect and easy-to-detect in an unsupervised manner: it
is hard to detect local small lesions, such as brain abscess and enhanced lesions;
but, it is easy to detect hyper-intense enhancing lesions, such as brain metastases
(AUC 0.921), especially for 7-SA MADGAN thanks to its feature recalibration. Our
visualization of differences between real/reconstructed slices might play a key role
in understanding and preventing various diseases, including rare disease.
As future work, we will investigate more suitable SA modules in a reconstruc-
tion model, such as Dual Attention Network that capture feature dependencies in
both spatial/channel dimensions [51]; here, optimizing where to place how many SA
modules is the most relevant aspect. We will validate combining new loss functions
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for both reconstruction/diagnosis, including sparsity regularization [52], structural
similarity [53], and perceptual loss [54]. Lastly, we plan to collect a higher amount
of healthy T1c scans to reliably detect and locate various diseases, including cancers
and rare diseases. Integrating multi-modal imaging data, such as Positron Emission
Tomography with specific radiotracers [55], might further improve disease diagno-
sis [56], even when analyzed modalities are not always available [57].
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Figure 1 Unsupervised medical anomaly detection framework: we train WGAN-GP w/ `1 loss on
3 healthy brain axial MRI slices to reconstruct the next 3 ones, and test it on both unseen healthy
and abnormal scans to classify them according to average `2 loss per scan.
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Figure 2 Proposed MADGAN architecture for the next 3-slice generation from the input 3
256× 176 brain MRI slices: 3-SA MADGAN has only 3 (red-contoured) SA modules after
convolution/deconvolution whereas 7-SA MADGAN has 7 (red- and blue-contoured) SA modules.
Similarly to RGB images, we concatenate adjacent 3 gray slices into 3 channels.
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Figure 3 Example T1 brain MRI slices with CDR = 0/0.5/1/2 from a test set: (a) Input 3 real
slices; (b) Ground truth next 3 real slices; (c, d) Next 3 slices reconstructed by MADGAN and
7-SA MADGAN. To compare the real/reconstructed next 3 slices, we show pixelwise `2 loss values
in (b) vs (c) and (b) vs (d) columns, respectively. Using a Jet colormap in [0, 0.2] with
alpha-blending, we overlay the obtained maps onto the ground truth slices. The achieved
slice-level `2 loss values are also displayed.
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Figure 4 Example T1c brain MRI slices with no abnormal findings/three brain metastases from a
test set: (a) Input 3 real slices; (b) Ground truth next 3 real slices; (c, d) Next 3 slices
reconstructed by MADGAN and 7-SA MADGAN. To compare the real/reconstructed next 3
slices, we show pixelwise `2 loss values in (b) vs (c) and (b) vs (d) columns, respectively. Using a
Jet colormap in [0, 0.06] with alpha-blending, we overlay the obtained maps onto the ground truth
slices. The achieved slice-level `2 loss values are also displayed.
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Figure 5 Example T1c brain MRI slices with four different brain diseases from a test set: (a)
Input 3 real slices; (b) Ground truth next 3 real slices; (c, d) Next 3 slices reconstructed by
MADGAN and 7-SA MADGAN. To compare the real/reconstructed next 3 slices, we show
pixelwise `2 loss values in (b) vs (c) and (b) vs (d) columns, respectively. Using a Jet colormap in
[0, 0.06] with alpha-blending, we overlay the obtained maps onto the ground truth slices. The
achieved slice-level `2 loss values are also displayed.
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Figure 6 Distributions of average `2 loss per scan evaluated on T1 slices with CDR = 0/0.5/1/2
reconstructed by: (a) MADGAN and (b) 7-SA MADGAN.
Figure 7 Distributions of average `2 loss per scan evaluated on T1c slices with no abnormal
findings/brain metastases/various diseases reconstructed by: (a) MADGAN and (b) 7-SA
MADGAN.
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Figure 8 AUC performance on T1 scans using average `2 loss per scan under different training
steps (i.e., 150k, 300k, 600k, 900k, 1.8M steps). Unchanged CDR = 0 (i.e., cognitively healthy
population) is compared against: (a) all the other CDRs (i.e., dementia); (b) CDR = 0.5 (i.e.,
very mild dementia); (c) CDR = 1 (i.e., mild dementia); (d) CDR = 2 (i.e., moderate dementia).
Han et al. Page 17 of 21
Figure 9 AUC performance on T1c scans using average `2 loss per scan under different training
steps (i.e., 150k, 300k, 600k, 900k, 1.8M steps). No abnormal findings are compared against: (a)
brain metastases + various diseases; (b) brain metastases; (c) various diseases.
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Figure 10 Unsupervised anomaly detection results using average `2 loss per scan on reconstructed
T1 slices (ROCs and AUCs). Unchanged CDR = 0 (i.e., cognitively healthy population) is
compared against: (a) all the other CDRs (i.e., dementia); (b) CDR = 0.5 (i.e., very mild
dementia); (c) CDR = 1 (i.e., mild dementia); (d) CDR = 2 (i.e., moderate dementia). Each
model is trained for 1.8M steps.
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Figure 11 Unsupervised anomaly detection results using average `2 loss per scan on reconstructed
T1c slices (ROCs and AUCs). No abnormal findings are compared against: (a) brain metastases +
various diseases; (b) brain metastases; (c) various diseases. Each model is trained for 1.8M steps.
Han et al. Page 20 of 21
Table 1 AUC performance of unsupervised anomaly detection on T1 scans using average `2 loss
(among whole slices/continuous 10 slices exhibiting the highest loss) per scan. Unchanged CDR = 0
(i.e., cognitively healthy population) is compared against: Unchanged CDR = 0 (i.e., cognitively
healthy population) is compared against: (i) all the other CDRs (i.e., dementia); (ii) CDR = 0.5 (i.e.,
very mild dementia); (iii) CDR = 1 (i.e., mild dementia); (iv) CDR = 2 (i.e., moderate dementia).
Each model is trained for 1.8M steps.
CDR = 0 vs CDR = 0.5 + 1 + 2 CDR = 0.5 CDR = 1 CDR = 2
MADGAN 0.768 0.750 0.797 0.829
MADGAN (10 slices) 0.764 0.745 0.793 0.830
MADGAN w/o `1 Loss 0.693 0.689 0.699 0.711
MADGAN w/o `1 Loss (10 slices) 0.705 0.697 0.717 0.736
3-SA MADGAN 0.752 0.736 0.775 0.835
3-SA MADGAN (10 slices) 0.739 0.725 0.760 0.810
3-SA MADGAN w/o `1 Loss 0.728 0.715 0.748 0.785
3-SA MADGAN w/o `1 Loss (10 slices) 0.735 0.721 0.756 0.806
7-SA MADGAN 0.765 0.743 0.800 0.832
7-SA MADGAN (10 slices) 0.764 0.743 0.798 0.835
7-SA MADGAN w/o `1 Loss 0.759 0.727 0.809 0.894
7-SA MADGAN w/o `1 Loss (10 slices) 0.746 0.710 0.803 0.868
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Table 2 AUC performance of unsupervised anomaly detection on T1c scans using average `2 loss
(among whole slices/continuous 10 slices exhibiting the highest loss) per scan. No abnormal findings
are compared against: (i) brain metastases + various diseases; (ii) brain metastases; (iii) various
diseases. Each model is trained for 1.8M steps.
Normal vs BM + VD BM VD
MADGAN 0.765 0.888 0.618
MADGAN (10 slices) 0.769 0.905 0.607
MADGAN w/o `1 Loss 0.688 0.773 0.586
MADGAN w/o `1 Loss (10 slices) 0.696 0.778 0.597
3-SA MADGAN 0.756 0.859 0.633
3-SA MADGAN (10 slices) 0.760 0.871 0.626
3-SA MADGAN w/o `1 Loss 0.677 0.749 0.589
3-SA MADGAN w/o `1 Loss (10 slices) 0.708 0.780 0.622
7-SA MADGAN 0.781 0.921 0.613
7-SA MADGAN (10 slices) 0.776 0.917 0.608
7-SA MADGAN w/o `1 Loss 0.233 0.063 0.436
7-SA MADGAN w/o `1 Loss (10 slices) 0.234 0.091 0.405
